Methotrexaat Sandoz (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, reducing tetrahydrofolate levels needed for DNA, RNA and protein synthesis. This limits the proliferation of immune and cancer cells. The drug also increases extracellular adenosine, which dampens inflammatory signalling pathways.

The dose of Methotrexaat Sandoz is individualized. A qualified prescriber determines the amount, frequency and duration based on the specific condition, patient weight, renal function and other clinical factors. No standard dosing regimen is provided here.

Methotrexaat Sandoz is contraindicated in pregnancy because it can cause fetal malformations and loss. Women of child‑bearing potential must use effective contraception. Limited data exist for breastfeeding; the drug is generally avoided while nursing.

To request Methotrexaat Sandoz, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Compared with other disease‑modifying antirheumatic drugs such as leflunomide or biologic agents, methotrexate offers oral administration and a long‑track record of efficacy. It may be less costly but requires regular laboratory monitoring for toxicity, whereas biologics often have higher acquisition costs and different safety profiles.

Methotrexaat Sandoz should be stored below 25 °C, in the original packaging, protected from moisture and direct sunlight. Keep the product out of reach of children and do not use if the packaging is damaged.

The medication is taken orally, usually with a full glass of water. It can be taken with or without food, but patients should follow the prescriber’s instructions regarding timing and whether a folic‑acid supplement is recommended.

Key serious risks include severe liver toxicity, pulmonary fibrosis or interstitial pneumonitis, life‑threatening infections due to bone‑marrow suppression, and renal failure. Patients should report persistent cough, jaundice, unusual bruising or signs of infection promptly.

Methotrexaat Sandoz should not be used by pregnant women, individuals with severe hepatic or renal impairment, patients with known hypersensitivity to methotrexate, or those receiving live vaccines. Contraindications are confirmed by the prescribing clinician.